hVIVO plc Director's Dealings (1260N)

TIDMHVO

RNS Number : 1260N

hVIVO plc

14 May 2015

For immediate release 7.00am: 14 May 2015

HVIVO PLC

("hVIVO" or the "Company")

Director's Dealings

hVIVO plc (AIM: HVO), the pioneer of human challenge models of disease, was notified on 13 May 2015 that the following Director's dealings took place on 13 May 2015:

-- Graham Yeatman, a Director of the Company, transferred a total of 60,000 ordinary shares of 5 pence each in the Company ("Ordinary Shares") to his spouse, Sonja Yeatman, for GBPnil consideration.

-- Graham Yeatman sold a total of 3,701 Ordinary Shares held outside his individual savings account ("ISA") at a price of 300.00 pence per Ordinary Share. Mr Yeatman then purchased 3,701 Ordinary Shares inside his ISA at a price of 300.80 pence per Ordinary Share.

-- Sonja Yeatman sold a total of 3,701 Ordinary Shares held outside her ISA at a price of 300.00 pence per Ordinary Share. Mrs Yeatman then purchased 3,701 Ordinary Shares inside her ISA at a price of 300.80 pence per Ordinary Share.

Following these transactions, there has been no change to the total beneficial holding of Mr Yeatman, and he continues to be interested in 185,200 Ordinary Shares (which represents approximately 0.3% of the Company's issued share capital). 62,700 Ordinary Shares are registered in the name of Mr Yeatman and 122,500 Ordinary Shares are registered in the name of Mrs Yeatman and their children.

For further information please contact:

hVIVO plc [phone]

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries [phone] / [phone]

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited [phone]

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 40 clinical studies, involving more than 1950 volunteers for a range of leading industry, governmental and academic clients.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSGGUCUAUPAPPW